212 related articles for article (PubMed ID: 19170711)
21. An X-linked NDI mutation reveals a requirement for cell surface V2R expression.
Sadeghi HM; Innamorati G; Birnbaumer M
Mol Endocrinol; 1997 Jun; 11(6):706-13. PubMed ID: 9171234
[TBL] [Abstract][Full Text] [Related]
22. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.
Gitelman SE; Feldman BJ; Rosenthal SM
Am J Med; 2006 Jul; 119(7 Suppl 1):S54-8. PubMed ID: 16843086
[TBL] [Abstract][Full Text] [Related]
23. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus.
Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N
J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106
[TBL] [Abstract][Full Text] [Related]
24. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.
Szalai L; Sziráki A; Erdélyi LS; Kovács KB; Tóth M; Tóth AD; Turu G; Bonnet D; Mouillac B; Hunyady L; Balla A
Front Pharmacol; 2022; 13():811836. PubMed ID: 35153784
[TBL] [Abstract][Full Text] [Related]
25. A case of a novel mutant vasopressin receptor-dependent nephrogenic diabetes insipidus with bilateral non-obstructive hydronephrosis in a middle aged man: differentiation from aquaporin-dependent nephrogenic diabetes insipidus by response of factor VII and von Willebrand factor to 1-diamino-8-arginine vasopressin administration.
Miyakoshi M; Kamoi K; Uchida S; Sasaki S
Endocr J; 2003 Dec; 50(6):809-14. PubMed ID: 14709855
[TBL] [Abstract][Full Text] [Related]
26. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus.
Postina R; Ufer E; Pfeiffer R; Knoers NV; Fahrenholz F
Mol Cell Endocrinol; 2000 Jun; 164(1-2):31-9. PubMed ID: 11026555
[TBL] [Abstract][Full Text] [Related]
27. AVPR2 variants and V2 vasopressin receptor function in nephrogenic diabetes insipidus.
Wildin RS; Cogdell DE; Valadez V
Kidney Int; 1998 Dec; 54(6):1909-22. PubMed ID: 9853256
[TBL] [Abstract][Full Text] [Related]
28. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
Bichet DG; Bockenhauer D
Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
[TBL] [Abstract][Full Text] [Related]
29. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
[TBL] [Abstract][Full Text] [Related]
30. Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.
Vandergheynst F; Pradier O; Beukinga I; Kornreich A; Vassart G; Decaux G
Eur J Clin Invest; 2012 Mar; 42(3):254-9. PubMed ID: 21834801
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants.
Kuramoto R; Kise R; Kanno M; Kawakami K; Ikuta T; Makita N; Inoue A
PLoS One; 2024; 19(5):e0303507. PubMed ID: 38748623
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
Robben JH; Deen PM
BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
[TBL] [Abstract][Full Text] [Related]
33. V2 vasopressin receptor mutations.
Makita N; Manaka K; Sato J; Iiri T
Vitam Horm; 2020; 113():79-99. PubMed ID: 32138955
[TBL] [Abstract][Full Text] [Related]
34. V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology.
Erdélyi LS; Hunyady L; Balla A
Front Endocrinol (Lausanne); 2023; 14():1173601. PubMed ID: 37293495
[TBL] [Abstract][Full Text] [Related]
35. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.
Birnbaumer M; Gilbert S; Rosenthal W
Mol Endocrinol; 1994 Jul; 8(7):886-94. PubMed ID: 7984150
[TBL] [Abstract][Full Text] [Related]
36. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
Bichet DG; Turner M; Morin D
Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
[TBL] [Abstract][Full Text] [Related]
37. Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene.
Faerch M; Christensen JH; Corydon TJ; Kamperis K; de Zegher F; Gregersen N; Robertson GL; Rittig S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):395-403. PubMed ID: 17941907
[TBL] [Abstract][Full Text] [Related]
38. Nephrogenic diabetes insipidus.
Bichet DG
Am J Med; 1998 Nov; 105(5):431-42. PubMed ID: 9831428
[TBL] [Abstract][Full Text] [Related]
39. Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant.
Janovick JA; Spicer TP; Bannister TD; Smith E; Ganapathy V; Scampavia L
Biochem J; 2018 Sep; 475(18):2941-2953. PubMed ID: 30068530
[TBL] [Abstract][Full Text] [Related]
40. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
Boone M; Kortenoeven M; Robben JH; Deen PM
Nephrol Dial Transplant; 2010 Jan; 25(1):48-54. PubMed ID: 19666909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
